Physician profile
Robert Eugene Olexo
NPI 1518968031
$1,321.19
in general payments reported to CMS, 2019-2025
11 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.40 · 2020: $76.61 · 2021: $113 · 2022: $162 · 2023: $140 · 2024: $278 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $297.90 | 2024-2025 | Zoryve |
| Abbvie INC. | $250.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $247.94 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $161.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $115.29 | 2019-2025 | |
| Lilly USA, LLC | $90.91 | 2019-2024 | Mounjaro |
| Amgen INC. | $89.37 | 2022-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $21.20 | 2022 | |
| Abbott Laboratories | $19.69 | 2024 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $14.59 | 2020 | |
| Amarin Pharma, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Olexo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.